65880-18-4

Basic information

• Product Name: ethyl 4,5,6,7-tetrahydro-1H-indole-2-carboxylate
• Synonyms: ethyl 4,5,6,7-tetrahydro-1H-indole-2-carboxylate;1H-Indole-2-carboxylic acid, 4,5,6,7-tetrahydro-, ethyl ester
• CAS NO: 65880-18-4
• Molecular Formula: C₁₁H₁₅NO₂
• Molecular Weight: 193.2423
• Mol File: 65880-18-4.mol
• Article Data: 14

Chemical Properties

• Melting Point: 98-100 °C(Solv: ethanol (64-17-5))
• Boiling Point: 373.4°C at 760 mmHg
• Flash Point: 179.6°C
• Appearance: /
• Density: 1.143g/cm³
• Vapor Pressure: 9.01E-06mmHg at 25°C
• Refractive Index: 1.55
• PKA: 16.27±0.20(Predicted)
• CAS DataBase Reference: ethyl 4,5,6,7-tetrahydro-1H-indole-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4,5,6,7-tetrahydro-1H-indole-2-carboxylate(65880-18-4)
• EPA Substance Registry System: ethyl 4,5,6,7-tetrahydro-1H-indole-2-carboxylate(65880-18-4)

Safety Data

• Hazardous Substances Data: 65880-18-4(Hazardous Substances Data)

Usage

General Description

Ethyl 4,5,6,7-tetrahydro-1H-indole-2-carboxylate is a chemical compound with the molecular formula C13H17NO2. It is an ester of indole-2-carboxylic acid and ethyl alcohol. ethyl 4,5,6,7-tetrahydro-1H-indole-2-carboxylate is commonly used as a precursor in the synthesis of various pharmaceuticals and industrial chemicals. It exhibits biological activity and has been studied for its potential therapeutic applications, particularly in the field of medicinal chemistry. The compound is also of interest in the development of new materials and research in the field of organic chemistry. Overall, ethyl 4,5,6,7-tetrahydro-1H-indole-2-carboxylate has a range of potential uses and applications in various scientific and industrial disciplines.

InChI:InChI=1/C11H15NO2/c1-2-14-11(13)10-7-8-5-3-4-6-9(8)12-10/h7,12H,2-6H2,1H3

Upstream product

• 82721-86-6 ethyl [(2-oxocyclohexyl)sulfanyl]methanethioate 
• 500801-00-3 2-ethanesulfonylamino-acrylic acid ethyl ester 
• 64-17-5 ethanol 
• 1346672-30-7 2,2,2-trichloro-1-(4,5,6,7-tetrahydro-1H-indol-2-yl)ethanone 
• 194534-89-9 ethyl 3-(2-chlorocyclohex-1-enyl)acrylate 
• 70-23-5 ethyl Bromopyruvate 
• 13618-91-2 4,5,6,7-tetrahydroindole 
• 141-52-6 sodium ethanolate 
• 81852-50-8 ethyl α-azidoacrylate 
• 18709-01-8 cyclohexanone-2-carboxylic acid 
• 6651-36-1 1-(Trimethylsilyloxy)cyclohexene 
• 73472-94-3 ethyl 3-bromo-2-(hydroxyimino)propanoate 
• 670-80-4 4-cyclohexen-1-ylmorpholine 
• 6829-41-0 diethyl oximinomalonate 

Downstream Products

• 1346672-74-9 2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate 
• 1346672-75-0 2-bromo-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1346669-58-6 2-(2-(hydroxymethyl)-3-(1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridin-3-yl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1346669-61-1 2-(2-(hydroxymethyl)-3-(1-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1360086-13-0 C₃₀H₃₂N₆O₄ 
• 1346672-82-9 acetic acid 2-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-6-(1-oxo-3,4,6,7,8,9-hexahydro-1H-pyrazino[1,2-a]indol-2-yl)benzyl ester 
• 1346669-62-2 2-(2-(hydroxymethyl)-3-(1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridine-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1346672-84-1 2-(6-(1-cyclopropyl-1H-pyrazol-4-ylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1346669-63-3 2-(3-(6-(1-cyclopropyl-1H-pyrazol-4-ylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-(hydroxymethyl)phenyl)-3,4,6,7,8,9-hexahydro-pyrazino[1,2-a]indol-1(2H)-one 
• 1346673-21-9 2-(5-(5-(3-hydroxyazetidin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1346669-77-9 2-(3-(5-(5-(3-hydroxyazetidin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(hydroxymethyl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1346673-27-5 2-(1-methyl-5-(5-(1-methylpiperidin-4-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1346669-79-1 2-(2-(hydroxymethyl)-3-(1-methyl-5-(5-(1-methylpiperidin-4-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1346673-44-6 2-(5-(5-(4-ethylpiperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 

Relevant articles and documents

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties

In our continued effort to discover and develop best-in-class Bruton's tyrosine kinase (Btk) inhibitors for the treatment of B-cell lymphomas, rheumatoid arthritis, and systemic lupus erythematosus, we devised a series of novel tricyclic compounds that improved upon the druglike properties of our previous chemical matter. Compounds exemplified by G-744 are highly potent, selective for Btk, metabolically stable, well tolerated, and efficacious in an animal model of arthritis.

HETEROARYL PYRIDONE AND AZA-PYRIDONE AMIDE COMPOUNDS

Heteroaryl pyridone and aza-pyridone amide compounds of Formula (I) are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

ALKYLATED PIPERAZINE COMPOUNDS

Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.